Cigna's Q3 Earnings Soar on Strong Pharmacy Growth, Medicare Divestiture

TL;DR

**Cigna's Q3 numbers are a knockout, driven by pharmacy strength and a smart Medicare exit; buy the dip if there is one.**

AI Summary

Cigna Group reported robust financial performance for the three and nine months ended September 30, 2025. Total revenues for the three months increased to $69.75 billion from $63.69 billion in 2024, driven primarily by a significant rise in pharmacy revenues to $56.05 billion from $48.28 billion. Net income for the three-month period more than doubled to $1.97 billion, up from $825 million in the prior year, resulting in diluted EPS of $6.98 compared to $2.63. For the nine months, total revenues reached $202.43 billion, an increase from $181.47 billion in 2024, with pharmacy revenues contributing $158.34 billion. Shareholders' net income for the nine months surged to $4.72 billion from $2.01 billion, yielding diluted EPS of $17.52 versus $7.05. Key business changes include the divestiture of Medicare Advantage and related businesses to Health Care Services Corporation on March 19, 2025, impacting insurance customer receivables. The company also saw a substantial increase in net investment gains to $26 million for the quarter, a significant turnaround from a $921 million loss in 2024. Risks include increased allowances for credit losses, rising to $160 million from $84 million, and a decrease in cash and cash equivalents by $1.53 billion since December 31, 2024. Strategic outlook focuses on leveraging Evernorth Health Services for growth in pharmacy and care services, and Cigna Healthcare for comprehensive medical solutions.

Why It Matters

Cigna's impressive Q3 performance, particularly the surge in pharmacy revenues and net income, signals strong operational execution and strategic benefits from its Evernorth segment. The divestiture of Medicare Advantage assets, while reducing premiums, has streamlined Cigna Healthcare, potentially allowing for more focused growth in other areas. For investors, the significant increase in diluted EPS to $6.98 from $2.63 demonstrates enhanced profitability and shareholder value. Competitively, Cigna's robust pharmacy services position it strongly against rivals in the health services sector, while the reduction in cash and increased credit loss allowances warrant investor attention regarding liquidity and risk management.

Risk Assessment

Risk Level: medium — The risk level is medium due to a notable decrease in cash and cash equivalents from $7.55 billion at December 31, 2024, to $6.03 billion at September 30, 2025, representing a $1.52 billion reduction. Additionally, the allowance for current expected credit losses increased significantly to $160 million as of September 30, 2025, from $84 million as of December 31, 2024, indicating potential future credit quality concerns.

Analyst Insight

Investors should consider Cigna's strong earnings growth and strategic focus on pharmacy services as a positive indicator. Monitor the company's cash flow and credit loss allowances closely in future filings, but the current performance suggests a healthy underlying business. Consider Cigna for long-term growth in the healthcare sector.

Financial Highlights

revenue

$69,748M

operating Margin

3.7%

net Income

$1,973M

eps

$6.98

cash Position

$6,025M

revenue Growth

+9.5%

Revenue Breakdown

Key Numbers

• $69.75B — Total Revenues (Increased from $63.69B in Q3 2024, driven by pharmacy growth.)
• $1.97B — Net Income (More than doubled from $825M in Q3 2024.)
• $6.98 — Diluted EPS (Increased significantly from $2.63 in Q3 2024.)
• $56.05B — Pharmacy Revenues (Increased from $48.28B in Q3 2024, a primary growth driver.)
• $160M — Credit Loss Allowance (Increased from $84M at Dec 31, 2024, indicating higher credit risk.)
• $6.03B — Cash and Cash Equivalents (Decreased from $7.55B at Dec 31, 2024, impacting liquidity.)
• $26M — Net Investment Gains (Turnaround from a $921M loss in Q3 2024.)
• $4.72B — Nine-Month Shareholders' Net Income (Increased from $2.01B in the prior nine-month period.)

Key Players & Entities

• Cigna Group (company) — global health company
• Evernorth Health Services (company) — reportable segment for pharmacy and care services
• Cigna Healthcare (company) — reportable segment for medical and coordinated solutions
• Health Care Services Corporation (company) — acquirer of Medicare Advantage businesses
• Berkshire Hathaway Life Insurance Company of Nebraska (company) — reinsurer for variable annuity business
• Financial Accounting Standards Board (regulator) — issued new accounting guidance
• $69.75 billion (dollar_amount) — total revenues for three months ended September 30, 2025
• $1.97 billion (dollar_amount) — net income for three months ended September 30, 2025
• $160 million (dollar_amount) — allowance for current expected credit losses as of September 30, 2025
• $1.5 billion (dollar_amount) — capacity of accounts receivable factoring facility

FAQ

Risk Factors

• Increased Credit Loss Allowances [medium — financial]: The allowance for credit losses rose to $160 million from $84 million, indicating a higher perceived risk of uncollectible receivables. This increase suggests potential deterioration in the financial health of counterparties or a more conservative provisioning approach.
• Divestiture Impact on Receivables [low — operational]: The divestiture of Medicare Advantage and related businesses impacted insurance customer receivables. While not explicitly detailed as a risk, such significant business changes can introduce operational complexities and potential disruptions in revenue streams and collections.
• Net Investment Losses Turnaround [medium — market]: The company experienced a significant turnaround in net investment results, moving from a $921 million loss in Q3 2024 to a $26 million gain in Q3 2025. While positive, the volatility highlights sensitivity to market fluctuations and potential for future losses.
• Decreased Cash Position [medium — financial]: Cash and cash equivalents decreased by $1.53 billion to $6.03 billion from December 31, 2024. This reduction in liquidity could constrain operational flexibility or the ability to respond to unforeseen financial needs.

Industry Context

The health services and insurance industry is characterized by intense competition, evolving regulatory landscapes, and increasing pressure to control healthcare costs. Companies are focusing on integrated solutions, pharmacy benefit management, and value-based care models to drive growth and efficiency. Technological advancements and data analytics are becoming crucial for personalized care and operational optimization.

Regulatory Implications

Cigna operates within a highly regulated environment, particularly concerning healthcare services and insurance. Changes in government healthcare policies, reimbursement rates, and compliance requirements (e.g., HIPAA, ACA) pose ongoing risks. The company must continually adapt to new regulations and ensure robust compliance programs to avoid penalties and maintain operational integrity.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-03-19: Divestiture of Medicare Advantage and related businesses — This strategic move impacts the company's revenue mix and balance sheet, specifically affecting insurance customer receivables and premium revenues.
• 2025-09-30: End of Third Quarter — Reporting period for the unaudited financial results, showing significant revenue and net income growth compared to the prior year.

Glossary

Shareholders' Net Income

The portion of net income attributable to the company's common shareholders after accounting for preferred dividends and noncontrolling interests. (Represents the profit available to Cigna's owners and is a key driver of EPS.)

Diluted EPS

Earnings per share calculated by dividing net income by the weighted-average number of outstanding common shares, including the dilutive effect of stock options and convertible securities. (Provides a more conservative measure of profitability on a per-share basis, reflecting potential dilution.)

Noncontrolling Interests

The portion of equity in a subsidiary that is not owned by the parent company. It represents the claims of outside shareholders on the subsidiary's net income and net assets. (Important for understanding the true net income attributable to Cigna's shareholders.)

Allowance for credit losses

A contra-asset account that reduces the carrying amount of accounts receivable to their net realizable value, representing an estimate of uncollectible amounts. (An increase indicates higher perceived credit risk among Cigna's customers.)

Net investment gains (losses)

The profit or loss realized from the sale or disposition of investments, or unrealized gains or losses on investments still held. (Can be a significant contributor to or detractor from overall net income, especially in volatile markets.)

Year-Over-Year Comparison

Cigna Group demonstrated strong year-over-year performance in the third quarter of 2025. Total revenues increased by 9.5% to $69.75 billion, primarily fueled by a substantial 16.1% surge in pharmacy revenues. Net income more than doubled, reaching $1.97 billion, leading to a significant improvement in diluted EPS to $6.98 from $2.63. While investment gains turned positive, the company also saw an increase in its allowance for credit losses and a reduction in its cash position, indicating evolving financial risk factors.

Key Financial Figures

• $0.01 — ich registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc. Ind

Filing Documents

• ci-20250930.htm (10-Q) — 2746KB
• exh_31125q3.htm (EX-31.1) — 9KB
• exh_31225q3.htm (EX-31.2) — 9KB
• exh_32125q3.htm (EX-32.1) — 4KB
• exh_32225q3.htm (EX-32.2) — 4KB
• ci-20250930_g1.jpg (GRAPHIC) — 147KB
• 0001739940-25-000037.txt ( ) — 16566KB
• ci-20250930.xsd (EX-101.SCH) — 137KB
• ci-20250930_cal.xml (EX-101.CAL) — 241KB
• ci-20250930_def.xml (EX-101.DEF) — 624KB
• ci-20250930_lab.xml (EX-101.LAB) — 1280KB
• ci-20250930_pre.xml (EX-101.PRE) — 916KB
• ci-20250930_htm.xml (XML) — 3131KB

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 3 Consolidated Statements of Income 3 Consolidated Statements of Comprehensive Income 4 Consolidated Balance Sheets 5 Consolidated Statements of Changes in Total Equity 6 Consolidated Statements of Cash Flows 8 Notes to the Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 34

Quantitative and Qualitative Disclosures A bout Market Risk

Item 3. Quantitative and Qualitative Disclosures A bout Market Risk 48

Controls and Procedures

Item 4. Controls and Procedures 48 PART II OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 49

Risk Factors

Item 1A. Risk Factors 49

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49

Other Information

Item 5. Other Information 49

Exhibits

Item 6. Exhibits 50 SIGNATURE 51 As used herein, the term "Company" refers to one or more of The Cigna Group and its consolidated subsidiaries.

FINANCIAL INFORMATION

Part I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

Item 1. FINANCIAL STATEMENTS The Cigna Group Consolidated Statements of Income Unaudited Unaudited Three Months Ended September 30, Nine Months Ended September 30, (In millions, except per share amounts) 2025 2024 2025 2024 Revenues Pharmacy revenues $ 56,054 $ 48,284 $ 158,336 $ 135,421 Premiums 9,081 11,436 30,973 34,493 Fees and other revenues 4,380 3,889 12,412 10,862 Net investment income 233 85 707 696 TOTAL REVENUES 69,748 63,694 202,428 181,472 Benefits and expenses Pharmacy and other service costs 55,530 47,565 157,196 133,488 Medical costs and other benefit expenses 7,842 9,527 26,089 28,482 Selling, general and administrative expenses 3,362 3,590 11,008 10,979 Amortization of acquired intangible assets 436 436 1,280 1,279 TOTAL BENEFITS AND EXPENSES 67,170 61,118 195,573 174,228 Income from operations 2,578 2,576 6,855 7,244 Interest expense and other ( 347 ) ( 376 ) ( 1,046 ) ( 1,073 ) Gain (loss) on sale of businesses 38 ( 87 ) 79 ( 106 ) Net investment gains (losses) 26 ( 921 ) 76 ( 2,805 ) Income before income taxes 2,295 1,192 5,964 3,260 TOTAL INCOME TAXES 322 367 950 1,018 Net income 1,973 825 5,014 2,242 Less: Net income attributable to noncontrolling interests 105 86 291 232 SHAREHOLDERS' NET INCOME $ 1,868 $ 739 $ 4,723 $ 2,010 Shareholders' net income per share Basic $ 7.02 $ 2.65 $ 17.65 $ 7.13 Diluted $ 6.98 $ 2.63 $ 17.52 $ 7.05 The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements. 3 The Cigna Group Consolidated Statements of Comprehensive Income Unaudited Unaudited Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2025 2024 2025 2024 Net income $ 1,973 $ 825 $ 5,014 $ 2,242 Other comprehensive income (loss), net of tax Net unrealized (depreciation) appreciation on securities and derivatives ( 401 ) 264 ( 180 ) 493 Net long-duration insurance and contractholder liabilities measurement adjustme